BSMO meeting materials – Archive

23rd BSMO virtual annual meeting 2021

Presentations Saturday 6 February

09:00 Lecture renal cell carcinoma – chair Sylvie Rottey, UZ Gent
Systemic treatment of RCC – Viktor Grünwald, University hospital Essen, Germany
09:45 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials – Elisa Agostinetto, Institut Jules Bordet
09:55 Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer – Hannah Van Belle, KU Leuven
10:05 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020 – Sofie Demasure, UZ Leuven
10:15 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic  review and meta-analysis –  Rafael Caparica, Institut Jules Bordet
10:25 Colchicine as salvage for refractory pyrexia due to BRAF and MEK inhibitors: a case report –Michael Saerens, UZ Gent
10:55 Round table discussion rectal cancer – chair Joelle Collignon, CHU de Liège
The changing landscape of neoadjuvant therapy in rectal cancer – Jeroen Dekervel, UZ Leuven
Followed by a 15 min discussion with J. Collignon (CHU de Liège), J. Dekervel (UZ Leuven), Willem Lybaert (AZ Nikolaas) and Ines Joye (Iridium)
11:30 Round table discussion breast cancer – chair Evandro de Azambuja, Institut Jules Bordet
11:31 Escalation and de-escalation strategies in early breast cancer – Donatienne Taylor, St Elisabeth, Namur
11:43 New insights in the treatment of advanced triple-negative breast cancer –Kevin Punie, UZ Leuven
Followed by a 15 min discussion with E. de Azambuja (Institut Jules Bordet), D. Taylor (St Elisabeth Namur) and K. Punie (UZ Leuven)
12:10 Keynote lecture – chair Kevin Punie, UZ Leuven
Hereditary Cancer Syndromes: What the oncologist should know – Robin De Putter, UZ Gent
12:50 Pfizer Award – chair Sylvie Rottey, UZ Gent
The development, implementation and evaluation of an AYA-MOC in Belgium – Nathalie Belpame, UZ Gent (MP4)
13:00 BSMO Projects – chair Joelle Collignon, CHU de Liège
13:00 COVID-19 in hospitalized patients with solid cancer in Belgium: The BSMO COVID project – Mariana Brandao, Institut Jules Bordet
13:10 BSMO project – Immunomanager v 2.0: National multidisciplinary immunotox board – Sandrine Aspeslagh, UZ Brussel

 

22nd Annual BSMO meeting 2020

Presentations Friday 14 February

10:00 Breast cancer task force
Optimal adjuvant endocrine treatment in premenopausal patients with HR+/HER2-negative breast cancer Insights from clinical trials – Francois Duhoux, UC Louvain
Neoadjuvant treatment considerations in HER2-positive breast cancer: Insights from clinical trials – Evandro De Azambuja, Institut Jules Bordet
Gene expression profiling in early breast cancer in the context of the Belgian pilot project – Donatienne Taylor, CHU UCL NAMUR Sainte-Elisabeth
13:30 Onco-geriatrics – Lore Decoster, UZ Brussel
14:30 HCC – Ivan Borbath, UCL
15:00 Cardio-oncology – Marie Moonen, CHU de Liege
16:00 O.01 Surgical treatment of hepatic metastases from oligometastatic breast cancer: the histopathological growth pattern of liver metastases as a predictor of postoperative outcome – an emerging biomarker? – Emily Latacz, GZA Hospitals & University of Antwerp
16:10 O.02 Relapsing and non-relapsing patients with luminal breast cancer exhibit differential plasma expression of several chemokines and microRNAs at diagnosis – Yentl Lambrechts, KU Leuven
16:20 O.03 Immune cell infiltration in cervical tumor tissue as a marker for response to (chemo) radiotherapy – Lien Lippens, Ghent University
16:30 O.04 Tumor sequencing is useful to reclassify germline variants in unexplained high-risk breast cancer families – Cédric Van Marcke, Cliniques universitaires Saint-Luc
16:40 O.05 c-MET as a potential resistance mechanism to everolimus in breast cancer; from a case report to patient cohort analysis – Valentin Van den Bossche, UC Louvain
16:50 O.06 The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: preliminary results of a randomized, placebo-controlled trial – Joy Lodewijckx, Hasselt University
17:00 O.07 Prognostic value of TILs evaluation with a standardized method in oropharynxcarcinoma – Stijn De Keukeleire, UZ Gent
17:10 O.08 Evaluating the impact of metformine on breast cancer aggressiveness and on chemotherapy efficacy: A retrospective and translational cohort analysis – Natasha Honoré, UCL, Woluwe Saint-Lambert

Presentations Saturday 15 February

08:45 BSMO supportive Taskforce (for members of the taskforce)
09:15 Hematology for the medical oncologist – Stef Meers, AZ Klina
09:45 NGS – Kathleen Claes, and Joni Van Der Meulen, UZ Gent
11:15 Precision trials of the BSMO – Lore Decoster, UZ Brussel & Philippe Aftimos, Institut Jules BordetSofie Joris, UZ Brussel
11:35-12:15 Activities of different BSMO task forces
Urology – Sylvie Rottey, UZ Gent
Quality – Didier Verhoeven, AZ Klina, Brasschaat
Sarcoma – Christine Gennigens, CHU de Liege
Cancer survivorship & supportive care – Christel Fontaine, UZ Brussel
Hereditary cancer syndromes – Kevin Punie, UZ Leuven
12:15 Keynote lecture: Genomic Profiling – Christine Desmedt, UZ Leuven

21st Annual BSMO meeting 2019

Presentations Friday 22 February

10:00 General Assembly
11:00 Clinical management of first line triple negative breast cancer (cases RFS<1y, RFS >1y) Michail Ignatiadis, Institut Jules Bordet
11:30 Clinical management of first line triple negative breast cancer with BRCA mutation Jacques De Grève, UZ Brussel
12:00 Treatment algorythm ER positive HER2 negative advanced breast cancer Guy Jerusalem, CHU de Liège
14:00 Practice changing topics in breast cancer Francois Duhoux, UC Louvain
14:30 Practice changing topics in Sarcoma Christine Gennigens, CHU de Liège
15:00 Topics in lung cancer Lore Decoster, UZ Brussel
15:50 Pfizer award IREN : A multilingual decision aid to support cancer patients’ decisions about clinical trial participation Patrick Miqueu, Institut Jules Bordet
16:00 Topics in gastrointestinal NEN (neuroendocrine neoplasms) Karen Geboes, UZ Gent
16:30 Tissue agnostic oncology Hans Prenen, UZ Antwerpen
17:00 Immunotherapy induced arthritis Laurent de Bellefon, UC Louvain
17:30 Update on ovarian cancer Peter Vuylsteke, CHU UCL Namur

Presentations Saturday 23 February

09:15 Introduction Jacques De Grève, BSMO President
09:45 Translational research 2018 Luc Dirix, Iridum Kankernetwerk
10:15 Paper of the Year Identification of the tumour transition states occurring during [EMT. Nature. 2018 Apr;556(7702):463-468] Cédric Blanpain, ULB Brussel
11.15 O.01 Clinical outcome and prognostic factors in oligometastatic breast cancer Tatjana Geukens, UZ Leuven
11.25 O.02 Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy Cynthia D’Hondt, UZ Brussel
11.35 O.03 Ethnic paradigm in prostate cancer – does it really matter? Fadi Dalati, CHU Saint Pierre
11.45 O.04 The spatial localization of immune cells predicts prognosis and response to therapy in inflammatory breast cancer  Christophe Van Berckelaer, UZ Antwerpen
11.55 O.05 The role of follicular helper CD4 T cells in breast cancer anti-tumoral immune response Mireille diane Langouo Fontsa, Institut Jules Bordet
12.05 O.06 CTC0 in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-directed therapy Elisabeth De Meue, Sint Augustinus
12.15 O.07 Real-life value of follow-up FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemoradiation (CRT) or (chemo)radiation ([C]RT) preceded by induction chemotherapy (IC) Bert Van Den Heuvel, UZ Antwerpen
12.25 O.08 Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: a retrospective analysis Tim Wessels, UZ Leuven
12:45 Heuson Lecture:Lessons learned after two decades of translational research in early breast cancer trials Martine Piccart, Institut Jules Bordet